KDC-MN-280 – Kodiac biolabs

Plain-language summaryIntrigue 60 / 100

Dutasteride (Avodart) is the more aggressive cousin of finasteride, approved in 2002. It blocks both type I and type II 5-alpha-reductase (finasteride mainly hits type II), suppressing plasma DHT by 90 to 95 percent rather than 65 to 70 percent. That makes it more effective for prostate enlargement and, in head-to-head trials, slightly better for hair loss, but it also produces a higher rate of sexual side effects. The very long half-life (about five weeks) means the effect persists long after stopping. The post-finasteride-syndrome concern applies here too. Often used off-label for hair loss in patients who do not respond to finasteride. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

51/100

Canonical dual 5AR inhibitor with mature mechanism, strong evidence base, and limited research novelty

Look, dutasteride is not a frontier compound. FDA approval 2002, mechanism completely characterized, clinical literature extensive. But ‘mature’ doesn’t mean ‘worthless as a research tool,’ and that’s the nuance worth preserving here.

The core pharmacology: dutasteride inhibits both 5-alpha-reductase isozymes, type I (Ki approximately 0.6 nM) and type II (Ki approximately 0.3 nM). Finasteride is primarily a type II inhibitor. The practical consequence is plasma DHT suppression of 90 to 95 percent versus 65 to 70 percent for finasteride at steady state. If your research question requires near-complete androgen withdrawal at the tissue level without castration, dutasteride is the cleanest tool available. No other 5AR inhibitor comes close on DHT floor, which matters when the difference between partial and near-complete suppression is exactly what you’re trying to study.

That differentiation point is real and it keeps the bench value score honest. For investigators studying DHT-mediated signaling in prostate, scalp follicle, or neural tissue, the choice between partial or near-complete 5AR inhibition is not trivial. The 5-week plasma half-life is both a feature and a design constraint: steady state takes time to achieve and washout takes longer, so crossover study designs require careful planning. Investigators who haven’t accounted for the slow offset have burned time and reagents on what were effectively underpowered comparisons.

The evidence base is genuinely strong. Multiple phase 3 RCTs for BPH, a growing off-label AGA literature where it consistently outperforms finasteride on hair count endpoints, and replicated mechanism across independent labs. This is not a single-consortium situation, and thats worth something in a space where a lot of peptide and nootropic compounds rely on a handful of groups.

What we don’t like here is the novelty picture. There’s nothing left to discover about the core mechanism. The interesting questions now are downstream: what are the tissue-specific consequences of near-complete DHT suppression that partial inhibition misses? Are there neurological effects from deeper androgen withdrawal that inform post-finasteride syndrome biology? That’s where the living research is happening, and dutasteride is a tool in that work, not the subject of it.

We think investigators working on androgen biology, AGA mechanisms, or prostate signaling should have dutasteride available as a reference probe. It does what it says, reliably, in real people. But if you’re looking for something novel to anchor a research program, this isn’t it. It’s a well-lit room, not an unexplored one.

Novelty: 22
Mechanism promise: 35
In-category differentiation: 60
Evidence quality: 76
Translational signal: 73
Research bench value: 57

Rationale Dutasteride scores well on evidence and translational signal (FDA-approved 2002, multiple phase 3 RCTs, unambiguous 90-95% DHT suppression in humans) but takes a significant hit on novelty and mechanism promise because the pharmacology is completely mapped after two decades of clinical use. Differentiation is elevated because nothing in the 5AR class matches its suppression depth, preserving its value as the canonical reference probe for androgen biology research.

Dual 5-alpha-reductase I/II inhibitor

A 4-azasteroid dual 5-alpha-reductase inhibitor (types I and II); more complete DHT suppression than finasteride.

Abstract

Dutasteride ((5-alpha,17-beta)-N-{2,5-bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide; CAS 164656-23-9; molecular formula C27H30F6N2O2; molecular weight 528.53) is a 4-azasteroid dual 5-alpha-reductase inhibitor developed at GlaxoSmithKline and approved by the FDA in 2002 under the trade name Avodart. Distinct from finasteride by inhibition of both 5AR isozymes (type I Ki approximately 0.6 nM, type II Ki approximately 0.3 nM, both substantially more potent than finasteride at type II). Plasma DHT is reduced by approximately 90 to 95 percent at the 0.5 mg dose, compared to 65 to 70 percent for finasteride. Plasma half-life is approximately 5 weeks (the longest in the 5AR inhibitor class), reflecting tight tissue binding. Approved for benign prostatic hyperplasia; off-label use in androgenetic alopecia (often more effective than finasteride). The longer half-life means slower offset of effect on discontinuation but also slower washout for fertility planning. Sexual side effects parallel finasteride. Used as the canonical dual 5AR inhibitor in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-280Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-280

Dutasteride

Abstract

Read the full monograph